These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38826736)

  • 1. Corporate social responsibility and firm performance: Case of Kazakhstan.
    Katenova M; Qudrat-Ullah H
    Heliyon; 2024 May; 10(10):e31580. PubMed ID: 38826736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corporate Social Responsibility Disclosure: Responding to Investors' Criticism on Social Media.
    Zhang Y; Yang F
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do financial performance and firm's value affect the quality of corporate social responsibility disclosure: Moderating role of chief executive officer's power in China.
    Na C; Tian G; Rauf F; Naveed K
    Front Psychol; 2022; 13():925323. PubMed ID: 36059787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderating role of financial ratios in corporate social responsibility disclosure and firm value.
    Naseem MA; Lin J; Rehman RU; Ahmad MI; Ali R
    PLoS One; 2019; 14(4):e0215430. PubMed ID: 30998740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of voluntary disclosure on financial performance: Empirical study on manufacturing industry in Indonesia.
    Meiryani ; Huang SM; Soepriyanto G; Jessica ; Fahlevi M; Grabowska S; Aljuaid M
    PLoS One; 2023; 18(6):e0285720. PubMed ID: 37267373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market.
    Dănescu T; Popa MA
    Global Health; 2020 Dec; 16(1):117. PubMed ID: 33302949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can corporate social responsibility protect firm value during the COVID-19 pandemic?
    Qiu SC; Jiang J; Liu X; Chen MH; Yuan X
    Int J Hosp Manag; 2021 Feb; 93():102759. PubMed ID: 36919172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corporate social responsibility, internal control, and firm financial performance.
    Zhang L; Su W
    Front Psychol; 2022; 13():977996. PubMed ID: 36660285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the dynamics of capital structure, corporate governance, and corporate social responsibility in high- and low-leveraged US and Chinese firms.
    Mahmood AN; Arslan HM; Younas ZI; Komal B; Ali K; Mubeen M
    Environ Sci Pollut Res Int; 2023 Apr; 30(16):46204-46221. PubMed ID: 36710308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Corporate Social Responsibility Boosts Corporate Financial and Non-financial Performance: The Moderating Role of Ethical Leadership.
    Bouichou SI; Wang L; Zulfiqar S
    Front Psychol; 2022; 13():871334. PubMed ID: 35693531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nexus between corporate social responsibility and firm's perceived performance: evidence from SME sector of developing economies.
    Yumei H; Iqbal W; Nurunnabi M; Abbas M; Jingde W; Chaudhry IS
    Environ Sci Pollut Res Int; 2021 Jan; 28(2):2132-2145. PubMed ID: 32875447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Outbreak and Financial Performance of Chinese Listed Firms: Evidence From Corporate Culture and Corporate Social Responsibility.
    Sun Y; Li Y
    Front Public Health; 2021; 9():710743. PubMed ID: 34604155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nexus of the CSR disclosures and corporate financial performance: evidence from Asian countries climate policy uncertainty.
    Waris M; Din BH
    Environ Sci Pollut Res Int; 2024 Jan; 31(2):1995-2008. PubMed ID: 38049691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relationship Between CEO Duality and Business Firms' Performance: The Moderating Role of Firm Size and Corporate Social Responsibility.
    Mubeen R; Han D; Abbas J; Álvarez-Otero S; Sial MS
    Front Psychol; 2021; 12():669715. PubMed ID: 35035363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of China's Vaccine Incidents on the Operational Efficiency of Biopharmaceutical Companies.
    Chai KC; Tao R; Chang KC; Yang Y
    Front Public Health; 2020; 8():93. PubMed ID: 32322567
    [No Abstract]   [Full Text] [Related]  

  • 16. Did Corporate Social Responsibility Vaccinate Corporations Against COVID-19?
    Poursoleyman E; Mansourfar G; Hassan MK; Homayoun S
    J Bus Ethics; 2023 Feb; ():1-27. PubMed ID: 36743218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does CSR performance improve corporate immunity to the COVID-19 pandemic? Evidence from China's stock market.
    Tian J; Wang X; Wei Y
    Front Public Health; 2022; 10():956521. PubMed ID: 36052006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does CSR affect the cost of equity capital: Empirical evidence from the targeted poverty alleviation of listed companies in China.
    Yi Y; Xie B; Zhou L; Wei Y
    PLoS One; 2020; 15(2):e0227952. PubMed ID: 32032381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Financial Redundancy on Corporate Social Responsibility Performance: Evidence From Chinese Listed Firms.
    He L; Gan S; Zhong T
    Front Psychol; 2022; 13():882731. PubMed ID: 35664182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical leadership, corporate social responsibility, firm reputation, and firm performance: A serial mediation model.
    Nguyen NTT; Nguyen NP; Thanh Hoai T
    Heliyon; 2021 Apr; 7(4):e06809. PubMed ID: 33898855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.